News & Press review

Here you can find the latest news about Italfarmaco and the international press reviews.

Press review

The material contained in this section is intended for informational purposes only and is not promotional. This section is intended for journalists and media.

2024 – March 21

Business Wire

Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy

Read the article

2024 – March 19

Business Wire

Italfarmaco Publishes in The Lancet Neurology results from Phase 3 EPIDYS Study in Duchenne Muscular Dystrophy (DMD)

Read the article

2023 – September 05

Business Wire

Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy

Read the article

2023 – June 29

Business Wire

Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review

Read the article

2022 – June 25

Business Wire

Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy

Read the article